Christopher D. Delaney
Harvard University
5 Papers
1 Citations
Christopher D. Delaney is an academic researcher from Harvard University. The author has contributed to research in topics: Chromatin & Myeloid-Lymphoid Leukemia Protein. The author has an hindex of 3, co-authored 5 publications. Previous affiliations of Christopher D. Delaney include Memorial Sloan Kettering Cancer Center & Dana Corporation.
Chat about Author
Papers
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL -rearranged leukemia
Chun-Wei Chen,Richard Koche,Amit U. Sinha,Aniruddha J. Deshpande,Nan Zhu,Rowena Eng,John G. Doench,Haiming Xu,Scott H. Chu,Jun Qi,Xi Wang,Christopher D. Delaney,Kathrin M. Bernt,David E. Root,William C. Hahn,James E. Bradner,Scott A. Armstrong +16 more
TL;DR: The combination of SIRT1 activators and DOT1L inhibitors shows enhanced antiproliferative activity against MLL-rearranged leukemia cells, indicating that the dynamic interplay between chromatin regulators controlling the activation and repression of gene expression could provide novel opportunities for combination therapy.
261
A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response
Takayuki Hoshii,Takayuki Hoshii,Paolo Cifani,Zhaohui Feng,Zhaohui Feng,Chun-Hao Huang,Chun-Hao Huang,Richard Koche,Chun-Wei Chen,Chun-Wei Chen,Christopher D. Delaney,Christopher D. Delaney,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe,Alex Kentsis,Scott A. Armstrong,Scott A. Armstrong +17 more
TL;DR: Data identify a connection between the chromatin regulator SETD1A and the DNA damage response that is independent of histone methylation and suggests that targeting SETD 1A and cyclin K complexes may represent a therapeutic opportunity for AML and, potentially, for other cancers.
103
High-resolution characterization of gene function using single-cell CRISPR tiling screen.
Lu Yang,Anthony K. N. Chan,Kazuya Miyashita,Christopher D. Delaney,Xi Wang,Hongzhi Li,Sheela Pangeni Pokharel,Sandra Li,Mingli Li,Xiaobao Xu,Wei Lu,Qiao Liu,Nicole Mattson,Kevin Yining Chen,Jinhui Wang,Yate-Ching Yuan,David Horne,Steven T. Rosen,Yadira M. Soto-Feliciano,Zhaohui Feng,Takayuki Hoshii,Gang Xiao,Gang Xiao,Markus Müschen,Markus Müschen,Jianjun Chen,Jianjun Chen,Scott A. Armstrong,Chun-Wei Chen,Chun-Wei Chen,Chun-Wei Chen +30 more
TL;DR: This work presents sc-Tiling, which integrates a CRISPR gene-tiling screen with single-cell transcriptomic and protein structural analyses that enables the capacity to identify regulatory mechanisms within a gene-coding region that dictate gene activity and therapeutic response.
High-Density CRISPR Scan Identifies Functional Regions of DOT1L That Mediate Therapeutic Response in MLL-r Leukemia
Chun-Wei Chen,Lu Yang,Xi Wang,Anthony K. N. Chan,Christopher D. Delaney,Kazuya Miyashita,Yanchun Guo,Wen-Han Chang,Sandra Li,Sheela Pangeni Pokharel,Hongzhi Li,Yadira M. Soto-Feliciano,Takayuki Hoshii,Scott A. Armstrong +13 more
TL;DR: A high-density CRISPR scan approach to dissect the function of Dot1l coding regions in mouse MLL-AF9 leukemic cells revealed a significant depletion of clusters of sgRNA targeting the known functional regions including the lysine methyltransferase (KMT) core and the AF9-binding domains of DOT1L.
1
Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis
Daria G. Valerio,Haiming Xu,Haiming Xu,Chun-Wei Chen,Chun-Wei Chen,Takayuki Hoshii,Takayuki Hoshii,Meghan E. Eisold,Christopher D. Delaney,Christopher D. Delaney,Monica Cusan,Aniruddha J. Deshpande,Aniruddha J. Deshpande,Chun-Hao Huang,Amaia Lujambio,Yujun George Zheng,Johannes Zuber,Tej K. Pandita,Scott W. Lowe,Scott A. Armstrong,Scott A. Armstrong +20 more
TL;DR: It is established that the HAT activity of MOF is required to sustain MLL-AF9 leukemia and may be important for multiple AML subtypes, offering a rationale to pursue MOF inhibitors as a targeted approach to treat M LL-rearranged leukemias.